计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 1 篇同行评审文献引用。
Aripiprazole是一种人5-HT1A受体激动剂,Ki为4.2 nM。
阿立哌唑的主要成分为 3, 4 二氢-2-(1H) 喹啉酮。
阿立哌唑已被用于研究其对乳腺肿瘤发生的影响,通过逆转录病毒传递受体酪氨酸蛋白激酶 2 或 HRas 原癌基因、gtp 酶或通过转基因表达 Wnt-1(原癌蛋白)介导。也用于研究其对幼年自发性高血压大鼠的行为和神经化学作用。
阿立哌唑已被用于研究阿立哌唑对注意缺陷多动障碍 (ADHD) 模型幼年自发性高血压大鼠 (SHR) 的行为和神经化学的影响。
A selective dopamine D2-receptor antagonist showing autoreceptor agonist activity.
Information
Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity5-HT receptorpartial agonist.
In vitro
Aripiprazole binds with high affinity to both the G protein-coupled and uncoupled states of receptors. Aripiprazole potently activates D2 receptor-mediated inhibition of cAMP accumulation. Aripiprazole has highest affinity for h5-HT(2B)-, hD(2L)-, and hD(3)-dopamine receptors, but also has significant affinity (5-30 nM) for several other 5-HT receptors (5-HT(1A), 5-HT(2A), 5-HT(7)), as well as alpha(1A)-adrenergic and hH(1)-histamine receptors. Aripiprazole has less affinity (30-200 nM) for other G protein-coupled receptors, including the 5-HT(1D), 5-HT(2C), alpha(1B)-, alpha(2A)-, alpha(2B)-, alpha(2C)-, beta(1)-, and beta(2)-adrenergic, and H(3)-histamine receptors. Aripiprazole is an inverse agonist at 5-HT(2B) receptors and displays partial agonist actions at 5-HT(2A), 5-HT(2C), D(3), and D(4) receptors.
In vivo
Aripiprazole reduces extracellular 5-HIAA concentrations in the medial prefrontal cortex and striatum of drug-naive rats, but not in chronic Aripiprazole-pretreated rats. Aripiprazole, 0.1 mg/kg and 0.3 mg/kg, significantly increases dopamine release in the hippocampus of rats. Aripiprazole, 0.3 mg/kg, slightly but significantly increases dopamine release in the medial prefrontal cortex but not in the nucleus accumbens. Aripiprazole, 3.0 mg/kg and 10 mg/kg, significantly decreases dopamine release in the nucleus accumbens but not the medical prefrontal cortex. Aripiprazole, 0.3 mg/kg, transiently potentiates haloperidol (0.1 mg/kg)-induced dopamine release in the medial prefrontal cortex but inhibited that in the nucleus accumbens.
Cell Data
cell lines:
Concentrations:
Incubation Time:
Powder Purity:≥98%
| ALogP | 4.6 |
|---|